Nektar Therapeutics Reports That Court Denies Novo Nordisk A/S’s Motion For Preliminary Injunction Against Exubera

SAN CARLOS, Calif.--(BUSINESS WIRE)--Nektar Therapeutics (Nasdaq:NKTR) reported that Pfizer Inc said today that the U.S. District Court for the Southern District of New York has denied a motion for a preliminary injunction that would have blocked further sales of its inhalable insulin medication, Exubera®, in the U.S. The preliminary injunction was requested by Novo Nordisk as part of a patent infringement case that will be heard by the same court.
MORE ON THIS TOPIC